Dimerix secures A$34 million loan for kidney disease treatments

Dimerix Limited, a clinical-stage biopharmaceutical company developing treatments for kidney diseases, has secured a significant non-dilutive loan facility worth up to A$34 million, as announced on September 4, 2026. The agreement, reached with a syndicate of Australian and U.S. independent lenders, marks a substantial financial boost for the company's ongoing and future clinical programs.

"We are pleased to have received strong support from a diverse group of lenders, reflecting their confidence in Dimerix and our mission to advance treatments for serious kidney diseases," said Dr. Nina Webster, CEO and Managing Director of Dimerix. "This funding will enable us to focus on our key clinical milestones without diluting our shareholders."

The facility, which includes a previously announced A$10 million loan with SKIPTAN, provides Dimerix with the financial flexibility to fund its ACTION3 Phase 3 trial for DMX-200 and the Phase 2 trial of DMX-652 in Acute Kidney Injury. Notably, Dimerix has elected to draw down only 50% of the committed funds, amounting to A$17 million, to cover its currently planned activities. This disciplined approach aims to minimize costs and preserve shareholder value while ensuring the company can access additional capital if needed.

"Dimerix is uniquely focused on kidney diseases, a growing global health concern with limited treatment options," Dr. Webster added. "We are committed to developing innovative therapies that can improve and extend the lives of patients in urgent need."

The new funding will support Dimerix's efforts to advance DMX-200 and DMX-652, two key programs in its pipeline. DMX-200 is currently in Phase 3 clinical development for focal segmental glomerulosclerosis (FSGS), a rare and life-threatening kidney disease. DMX-652 is in Phase 2 development for Acute Kidney Injury, a condition associated with significant morbidity and healthcare costs.

"By leveraging this non-dilutive funding, Dimerix aims to accelerate its clinical programs and deliver meaningful benefits to patients," Dr. Webster stated. "We are excited about the potential of DMX-652 to prevent kidney injury and preserve renal function, as well as the ongoing progress of DMX-200 in the ACTION3 trial."

The facility provides Dimerix with the option to secure up to A$50 million in total commitments by March 31, 2027, although the company currently has no plans to access this additional funding. The terms of the facility are consistent with the previously announced SKIPTAN agreement, with minor amendments to standardize key terms across all lenders.

"Non-dilutive funding is crucial for companies like Dimerix, which are focused on developing new treatments with significant unmet medical needs," said Dr. Webster. "This facility will help us maintain our financial flexibility and pursue our mission to improve outcomes for patients with kidney diseases."

As Dimerix continues to advance its clinical programs, the company is on track to achieve key milestones, including the completion of the ACTION3 Phase 3 trial and the Phase 2 trial of DMX-652. The facility is expected to be repaid through existing and potential future milestone payments and capital market access.

"Dimerix's commitment to developing new treatments for kidney diseases and creating long-term value for shareholders remains unwavering," Dr. Webster concluded. "We are excited about the potential of our pipeline and the progress we have made to date."

This non-dilutive funding will support Dimerix's ongoing efforts to advance its late-stage pipeline and deliver innovative treatments to patients in urgent need.